Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA ...

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment ...

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, ...

Stanford Medicine researchers have developed a blood test capable of detecting cancers, the ways cancer resists treatments ...

Prostate cancer has distinct genetic properties in different groups of men that could be targeted to improve patient outcomes, new research suggests.

Genetic analysis reveals how chimeric RNA in prostate cancer varies across populations, offering new paths for precision ...

An artificial intelligence (AI)-based model developed by UT Southwestern Medical Center researchers can accurately predict ...

A new Stanford blood test detects cancer and tissue damage by analyzing rare RNA fragments in the blood. Stanford Medicine ...

US FDA grants breakthrough device designation to Roche’s companion diagnostic, VENTANA TROP2 (EPR20043) RxDx Device for non-small cell lung cancer: Basel Wednesday, April 30, 20 ...